Elicera and the EIC Accelerator: Armed CAR-T Shows Responses

CAR-T therapy re-engineers a patient's own T cells to attack cancer, and Elicera Therapeutics, based in Gothenburg, adds a weapon. Its iTANK platform makes the cells release a neutrophil-activating protein from the bacterium Helicobacter pylori, meant to call in the rest of the immune system and overcome problems such as tumours hiding their target and suppressing T cells, according to its EIC project.

The European Innovation Council granted €2,499,999 towards a €3.6 million project from October 2022 to September 2025 that paid for CARMA, the first human trial of ELC-301, a CD20-targeted CAR-T for B-cell lymphoma. The final report says six patients were treated in the first two dose cohorts, four with complete metabolic responses, at "only 10 to 30% of the intended maximum dose". In August 2026 Elicera reported that the Phase I part was complete, with tumour responses in 10 of 11 patients evaluated and no dose-limiting toxicities.

Where Elicera Stands Now

After the last Phase I patient, a safety board will set the dose for a Phase IIa expansion of six more patients. Of the 11 patients evaluated, six had a complete metabolic response and four of those remained disease-free at the latest follow-up. On 14 August 2026 the company corrected its release: of three patients previously treated with CAR-T, all had disease control but two, not three, had an objective tumour response. The founder handed over to a new CEO on 1 September 2026.

The Technology: CAR-T Cells That Call for Backup

The report also says Elicera finalised a manufacturing process with 17 days from blood collection to infusion, against a median of 54 days it cites for commercial CAR-T products. ELC-301 targets CD20, and one patient previously treated with a commercial CD19 CAR-T achieved a complete response in the EIC period. The trial is small and has no control arm.

What the EIC Project Promised, and What CORDIS Shows

The project promised clinical validation of the iTANK platform. It delivered a working manufacturing process and early human data with no severe or unexpected side effects in the EIC period, and the Phase I part finished a year later. The EIC's final payment was approved in 2026, according to the company's interim report. CORDIS still lists the project as signed.

1. First-in-human trialDeliveredPhase I complete, 2026.
2. SafetyShownNo dose-limiting toxicity.
3. Fast manufacturingDelivered17 days vein to vein.
4. Peer-reviewed resultsNot yetCompany releases only.

The Money

Elicera lost SEK 11.3 million in the first half of 2026. It pays for its trials through rights issues. In March 2024 only 43% of an issue was taken up, mostly by underwriters, bringing in SEK 27.6 million, according to the company's announcement. In 2026 it offered SEK 72.8 million and raised SEK 54.6 million.

What Cannot Be Checked

Why Europe Should Care

The EIC grant paid for a European biotech's first human trial, and the early results are among the strongest in this series. The company that owns them is small and has struggled to fill its share issues, which will decide how far the therapy gets.

The Verdict

Elicera Therapeutics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.